Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Poviztra is a second brand of Wegovy
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
These findings follow positive Phase 3 results presented earlier this year
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Subscribe To Our Newsletter & Stay Updated
